AAV Induced Expression of Human Rod and Cone Opsin in Bipolar Cells of a Mouse Model of Retinal Degeneration.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
09 Feb 2021
09 Feb 2021
Historique:
entrez:
25
4
2022
pubmed:
9
2
2021
medline:
27
4
2022
Statut:
ppublish
Résumé
Vision loss caused by inherited retinal degeneration affects millions of people worldwide, and clinical trials involving gene supplementation strategies are ongoing for select forms of the disease. When early therapeutic intervention is not possible and patients suffer complete loss of their photoreceptor cells, there is an opportunity for vision restoration techniques, including optogenetic therapy. This therapy provides expression of light-sensitive molecules to surviving cell types of the retina, enabling light perception through residual neuronal pathways. To this end, the bipolar cells make an obvious optogenetic target to enable upstream processing of visual signal in the retina. However, while AAV transduction of the bipolar cells has been described, the expression of human opsins in these cell types within a model of retinal degeneration (
Identifiants
pubmed: 35465048
doi: 10.1155/2021/4014797
pmc: PMC7612646
mid: EMS144310
doi:
Substances chimiques
Cone Opsins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Subventions
Organisme : Medical Research Council
ID : MR/V029762/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
Conflicts of Interest The authors declare that there is no conflict of interest.
Références
Mol Vis. 2011;17:1771-83
pubmed: 21750604
Nat Med. 2018 Oct;24(10):1507-1512
pubmed: 30297895
PLoS One. 2013 Apr 09;8(4):e60361
pubmed: 23593201
Nat Methods. 2014 Mar;11(3):338-46
pubmed: 24509633
Cell. 1994 May 6;77(3):361-9
pubmed: 8181056
Hum Mol Genet. 2015 Nov 1;24(21):6229-39
pubmed: 26310623
Mol Ther. 2015 Oct;23(10):1562-71
pubmed: 26137852
Mol Ther Methods Clin Dev. 2014 Jan 8;1:5
pubmed: 24761428
J Comp Neurol. 2004 Jan 26;469(1):70-82
pubmed: 14689473
Curr Biol. 2015 Aug 17;25(16):2111-22
pubmed: 26234216
Mol Ther. 2011 Jul;19(7):1220-9
pubmed: 21505421
Mol Ther. 2015 Jan;23(1):7-16
pubmed: 25095892
Nat Commun. 2019 Mar 15;10(1):1221
pubmed: 30874546
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11211-11216
pubmed: 28973921
Front Neurosci. 2020 Nov 11;14:570909
pubmed: 33262683
Nat Protoc. 2006;1(3):1412-28
pubmed: 17406430
N Engl J Med. 2015 May 14;372(20):1887-97
pubmed: 25938638
Mol Ther. 2011 Feb;19(2):293-301
pubmed: 21045809
Front Neurosci. 2017 Mar 29;11:161
pubmed: 28424574
Prog Retin Eye Res. 2003 Sep;22(5):607-55
pubmed: 12892644
Eur J Neurosci. 2009 Apr;29(8):1533-42
pubmed: 19385989
PLoS Biol. 2015 May 07;13(5):e1002143
pubmed: 25950461
Nat Med. 2020 Mar;26(3):354-359
pubmed: 32094925
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5574-83
pubmed: 25489083
Invest Ophthalmol Vis Sci. 2009 May;50(5):2328-36
pubmed: 19011017
J Comp Neurol. 2003 Sep 8;464(1):1-16
pubmed: 12866125
Mol Ther Methods Clin Dev. 2017 Dec 22;9:192-202
pubmed: 29766027
BMJ Open. 2014 Feb 12;4(2):e004015
pubmed: 24525390
Mol Ther. 2009 Dec;17(12):2096-102
pubmed: 19672248
Gene Ther. 2016 Aug;23(8-9):680-9
pubmed: 27115727
EMBO Mol Med. 2014 Aug 04;6(9):1175-90
pubmed: 25092770
Biochem Biophys Res Commun. 2020 Jun 25;527(2):325-330
pubmed: 31982136
Neuron. 2006 Apr 6;50(1):23-33
pubmed: 16600853
J Biol Chem. 1993 Jun 5;268(16):11868-73
pubmed: 8389366